Loading
Adavosertib is an oral serine/threonine kinase inhibitor from AstraZeneca, in registered phase 2 trials for triple-negative breast cancer.
Adavosertib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by AstraZeneca, in triple-negative breast cancer. A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family.
1.Adavosertib slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Adavosertib" OR ABSTRACT:"Adavosertib") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Adavosertib, not a curated reading list.
Shares AstraZeneca and the tags pipeline, registry-only.
Shares AstraZeneca and the tags pipeline, registry-only.
Shares Triple-negative breast cancer (TNBC) and the tags pipeline, registry-only.
Shares Triple-negative breast cancer (TNBC) and the tags pipeline, registry-only.
Shares AstraZeneca and the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.